# HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

> **NCT03596086** · PHASE1,PHASE2 · RECRUITING · sponsor: **David Baskin MD** · enrollment: 62 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Astrocytoma, Grade III

## Interventions

- **DRUG:** ADV/HSV-tk (gene therapy)

## Key facts

- **NCT ID:** NCT03596086
- **Lead sponsor:** David Baskin MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-11
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596086, "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03596086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*